Corporate Spotlight
Scott Law joins Telix as SVP Global Manufacturing Operations
11 June 2021 – Corporate Spotlight | Scott Law joins Telix as Senior Vice President Global Manufacturing Operations
Telix is delighted to announce that Scott Law has joined the Company as Senior Vice President, Global Manufacturing Operations.
Scott brings with him over 30 years’ global pharmaceutical experience, including senior manufacturing roles at companies such as Baxter, Emergent BioSolutions, Ferndale Laboratories, and Pfizer.
Most recently, Scott served as Vice President, Manufacturing and Operations at Cognate BioServices where he was responsible for the manufacture and commercialization of cell-based products.
Scott will lead Telix’s global manufacturing operations, with an initial focus on final launch preparation for Illuccix® (for prostate cancer imaging).
On joining Telix Scott stated, “It’s exciting to be joining Telix at this pivotal time in the advanced development of life-saving radiopharmaceuticals. I hope to use my experience in commercial pharmaceuticals and biotech to enhance this talented team and deliver products to market.”
We welcome Scott to the Telix team, as we work to deliver on our mission to help patients with cancer live longer, better quality lives.
Illuccix® has not received a marketing authorisation in any jurisdiction.
More Articles
ASX News
Telix Update on FDA New Drug Application Review for Illuccix®
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 17 June 2021. Telix announces participation in a late-cycle meeting with the U.S....
Corporate Spotlight
Telix Pharmaceuticals and Applied Radiology launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research
MELBOURNE, Australia and INDIANAPOLIS 14 June, 2021 – Telix announces the launch of a new educational platform focused on radiopharmaceutical...
Corporate Spotlight
Telix launches “Gallium Wave” Awareness Website
Melbourne (Australia) and Indianapolis (U.S.A.) – 11 June 2021. Telix announces the launch of a new website “Gallium Wave”, as...
Corporate Spotlight
Scott Law joins Telix as SVP Global Manufacturing Operations
11 June 2021 – Corporate Spotlight | Scott Law joins Telix as Senior Vice President Global Manufacturing Operations
ASX News
Telix and ATS Awarded $1.56M ‘Eurostars’ Grant for Alpha Therapy
Liège (Belgium) and Gothenburg (Sweden) – 7 June 2021. Advanced Nuclear Medicine Ingredients S.A, a wholly owned European subsidiary of...
ASX News
Telix and Eckert & Ziegler Sign US Co-Promotion Agreement for Prostate Cancer Imaging
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 3 June 2021. Telix announces co-promotion agreement with EZAG for Telix’s investigational prostate...
Corporate Spotlight
Cardinal Health and Telix Launch Gallium Awareness Campaign
Dublin (Ohio) and Indianapolis (Indiana) – 27 May 2021. Cardinal Health and Telix launch gallium awareness campaign with release of...
ASX News
TLX66 Meets Study Objectives in Patients with AL Amyloidosis
Melbourne (Australia) and Southampton (United Kingdom) – 25 May 2021. Telix announces bone marrow conditioning investigational candidate TLX66 has met...
ASX News
First Patient Dosed in Japanese Prostate Cancer Imaging Study
Melbourne (Australia) and Kyoto (Japan) – 25 May 2021. Telix announces the first patient has been dosed in a clinical...
ASX News
Telix Pharmaceuticals and Eckert & Ziegler Sign German Distribution Agreement for Prostate Cancer Imaging
Melbourne (Australia) and Berlin (Germany) – 18 May 2021. Telix has entered an exclusive commercial distribution agreement with Eckert &...
Corporate Spotlight
Telix at ANZSNM Annual Scientific Meeting
13 May 2021 – Clinical Spotlight | Telix to Sponsor Pre-Conference Symposium at 51st Australian and New Zealand Society of...
ASX News
Telix Pharmaceuticals Limited AGM 2021 – Chairman and CEO Addresses
Melbourne (Australia) 12 May 2021 – Telix provides the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting...
ASX News
Telix and Monrol Expand Alliance to Include Lutetium Supply
Melbourne (Australia) and Istanbul (Turkey) – 11 May 2021. Telix announces global clinical supply agreement with Monrol for the supply...
ASX News
Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy
Melbourne (Australia) – 10 May 2021. Telix has been granted HREC approval and received CTN clearance by the TGA to...
ASX News
Telix Announces Executive Leadership Appointments and Establishment of Asia Pacific Operating Region
Melbourne (Australia) – 3 May 2021. Telix announces several key executive leadership appointments, including the establishment of an Asia-Pacific (APAC)...
ASX News
Telix Pharmaceuticals Appoints Richard Valeix as EMEA President
Melbourne (Australia) and Herstal (Belgium) – 3 May 2021. Telix announces Richard Valeix has joined the Telix executive leadership team...
ASX News
Telix Pharmaceuticals and Global Medical Solutions Complete Strategic Manufacturing Agreement
Melbourne (Australia) and Henderson, NV (U.S.A.) – 27 April 2021. Telix announces it has completed a strategic manufacturing agreement with...
ASX News
Japanese Renal Cancer Imaging Trial Meets Study Objectives
Melbourne (Australia) and Kyoto (Japan) – 21 April 2021. Telix announces the Company’s ZIRDAC-JP study of its renal cancer imaging...
ASX News
Launch of the International NOBLE Registry of Telix’s SPECT-Based Prostate Cancer Imaging Agent
Melbourne (Australia) and Brussels (Belgium) – 19 April 2021. Telix announces the launch of the international NOBLE Registry of Telix’s...
ASX News
Telix Pharmaceuticals Limited – Notice of Annual General Meeting 2021
Melbourne (Australia) – 12 April 2021. Telix Pharmaceuticals provides notice of The Annual General Meeting of Shareholders on Wednesday 12...
ASX News
Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 31st March 2021. Telix announces it has completed an agreement with Grand River...
Corporate Spotlight
Telix Appoints Darren Patti, Chief Operating Officer, Telix Pharmaceuticals (US) Inc.
29th March 2021 – Corporate Spotlight | Darren Patti joins Telix as Chief Operating Officer, Telix Pharmaceuticals (US) Inc.
ASX News
Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply
Melbourne (Australia) and Garching (Germany) – 18th March 2021. Telix announces it has extended its non-exclusive global clinical and commercial supply...
Corporate Spotlight
Telix Appoints Sébastien Linard as General Manager, Telix European Manufacturing Facility
8th March 2021 – Corporate Spotlight | Sébastien Linard joins Telix as General Manager of Telix’s European Manufacturing in Seneffe,...
ASX News
Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply
Melbourne (Australia) and Garching (Germany) – 18th March 2021. Telix announces it has extended its non-exclusive global clinical and commercial...
ASX News
Telix Pharmaceuticals Releases Results for the Year Ended 31 December 2020 and 2020 Annual Report
Melbourne (Australia) – 26th February 2021. Telix Pharmaceuticals Limited Releases Full-Year 2020 Results and 2020 Annual Report.
ASX News
Telix and Kanazawa University Cleared to Commence Prostate Cancer Imaging Study in Japan
Melbourne (Australia) and Kyoto (Japan) – 22nd February 2021. Telix Japan receives Clinical Trial Notification (CTN) clearance to commence a...
ASX News
Telix FY2020 Results and Company Update Conference Call
Melbourne (Australia) – 16th February 2021. Telix to present the Company’s FY2020 results together with an update on Telix’s operations.
ASX News
Czech Republic Grants National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product
Melbourne (Australia) and Liège (Belgium) – 16th February 2021. Telix announces the Ministry of Health of the Czech Republic is...
ASX News
Telix and Heidelberg University Hospital to Develop Next Generation Theranostics
Melbourne (Australia) and Heidelberg (Germany) – 10th February 2021. Telix announces research cooperation agreement with Heidelberg University Hospital to develop...
Corporate Spotlight
Industry Leaders’ Round-Table at SNMMI Mid-Winter Satellite Symposium
3rd February 2021 | Corporate Spotlight – Recording of Industry Leaders’ Round-Table Discussion at SNMMI Mid-Winter Symposium: Ga-68 PSMA-11: Advances...
ASX News
First U.S. Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 25th January 2021. Telix Pharmaceuticals announces the first U.S. patients have been dosed...
Corporate Spotlight
ARTMS and Telix Pharmaceuticals Announce Successful Production of 68Ga PSMA-11 with Cyclotron Produced 68Ga from a Solid Target
Burnaby, Canada and Indianapolis, USA, January 12, 2021 – ARTMS Inc. and Telix announce successful production of Telix’s prostate cancer...
ASX News
Telix Pharmaceuticals Files New Drug Submission with Health Canada for Prostate Cancer Imaging Product
Melbourne (Australia) and Indianapolis, IN (USA) – 16th December 2020. Telix has filed a New Drug Submission (NDS) with Health Canada...
ASX News
Telix Pharmaceuticals and Mauna Kea Technologies Launch Urologic Oncology Alliance
Melbourne (Australia) – 16th December 2020. [Article updated with new video 16th February 2021] Telix Pharmaceuticals announces collaboration with Mauna...
ASX News
Telix and Kanazawa University Commence Japanese Clinical Study for Prostate Cancer Imaging
Melbourne (Australia) – 14th December 2020. Telix announces its subsidiary, Telix Pharmaceuticals Japan KK, has entered a clinical study collaboration...
ASX News
Telix Completes IP Agreement with the University of Southampton (UK) Granting Exclusive Access to TRALA Clinical Trial Data
Melbourne (Australia) – 14th December 2020. Telix Pharmaceuticals Limited announces today that its wholly-owned subsidiary TheraPharm GmbH has completed an...
ASX News
Telix Granted TGA Priority Review for Prostate Cancer Imaging
Melbourne (Australia) – 7th December 2020. Telix has been granted Priority Review status for TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the...
ASX News
Telix and DuChemBio Announce Korean Partnership for Advanced Prostate Cancer Imaging
Melbourne (Australia) and Seoul (South Korea) – 3rd December 2020. Telix Pharmaceuticals announces it has entered into a licensing and partnership...